Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Neoadjuvant Chemotherapy in Bladder Cancer

Neoadjuvant Chemotherapy in Bladder Cancer Despite radical cystectomy for muscle-invasive bladder cancer, approximately 50% of patients with this disease will develop metastatic progression. Neoadjuvant systemic chemotherapy can be administered to decrease the risk of recurrence. Multiple randomized trials have addressed the effect of neoadjuvant chemotherapy on survival in patients with muscle-invasive bladder cancer. A recently published meta-analysis demonstrated a survival benefit with cisplatin-based neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Neoadjuvant Chemotherapy in Bladder Cancer

Loading next page...
 
/lp/springer-journals/neoadjuvant-chemotherapy-in-bladder-cancer-gfhdXcMWAc

References (33)

Publisher
Springer Journals
Copyright
Copyright © 2005 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200504020-00001
Publisher site
See Article on Publisher Site

Abstract

Despite radical cystectomy for muscle-invasive bladder cancer, approximately 50% of patients with this disease will develop metastatic progression. Neoadjuvant systemic chemotherapy can be administered to decrease the risk of recurrence. Multiple randomized trials have addressed the effect of neoadjuvant chemotherapy on survival in patients with muscle-invasive bladder cancer. A recently published meta-analysis demonstrated a survival benefit with cisplatin-based neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.